These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3897173)

  • 1. Evaluation of the in-vivo efficacy of Sch 34343.
    Loebenberg D; Moss EL; Rudeen J; Menzel F; Hare RS; Oden EM; Lin CC; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():207-18. PubMed ID: 3897173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of anaerobic bacteria to Sch 34343 and other antibiotics.
    Glupczynski Y; Gordts B; van der Linden MP; Labbé M; Yourassowsky E; Butzler JP
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():193-8. PubMed ID: 4030548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.
    Dornbusch K; Frolander F; Cacciapuoti AF; Naples L; Hare RS; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():85-97. PubMed ID: 3897175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases.
    Shannon K; King A; Phillips I
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():15-23. PubMed ID: 3897169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in-vitro activity of Sch 34343 for a wide spectrum of clinically significant anaerobic bacteria.
    Wells CL; Wilkins TD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():177-82. PubMed ID: 4030546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
    Brook I
    Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro activity of Sch 34343 and other antimicrobial agents against anaerobic bacteria.
    Nord CE; Olsson-Liljequist B
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():183-8. PubMed ID: 2863246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity and beta-lactamase stability and inhibitory properties of a new penem antibiotic, Sch 34343.
    Neu HC; Chin NX; Labthavikul P
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():25-37. PubMed ID: 3875603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of Sch 34343 against anaerobic bacteria.
    Wexler H; Carter WT; Finegold SM
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():173-6. PubMed ID: 3861606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem.
    Andrew JH; Greenwood D
    J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of SCH 34343 against anaerobic bacteria.
    Sutter VL; Wexler H; Finegold SM
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):341-4. PubMed ID: 3698546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aspoxicillin on anaerobic bacteria.
    Ueno K; Watanabe K; Bunai M; Kobayashi T; Aoki M; Maezawa I; Sakuma Y; Yoshida H; Yamaguchi T
    Jpn J Antibiot; 1985 Jun; 38(6):1516-28. PubMed ID: 3850132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
    Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
    Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of latamoxef (moxalactam) against both Bacteroides fragilis and Escherichia coli in an intraperitoneal abscess model.
    Harris RW; Moore WL; Arensman JB; Rissing JP
    J Antimicrob Chemother; 1984 Nov; 14(5):499-508. PubMed ID: 6392279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacterial activity of MT-141 against anaerobic bacteria].
    Watanabe T; Hara T; Kasai T; Ishii T; Miyauchi K; Date H; Jinzaki M; Shindo H; Matsugami A; Goi H
    Jpn J Antibiot; 1984 Jun; 37(6):1058-69. PubMed ID: 6092738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.